In Brief: Endocrinologic & Metabolic Drugs Advisory Committee
Endocrinologic & Metabolic Drugs Advisory Committee: Two-day meeting is scheduled for Feb. 23 and 24. The committee will discuss Serono's Geref (sermorelin acetate, NDA 20-443) for growth hormone insufficiency on Feb. 23. Roussel Uclaf's NDA 20-169 for Anandron (nilutamide) for prostate cancer will be discussed Feb. 24. The meeting will begin at 8:30 a.m. both days at the Holiday Inn Silver Spring, Md...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth